195 related articles for article (PubMed ID: 27513855)
1. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.
Qirjazi E; McArthur E; Nash DM; Dixon SN; Weir MA; Vasudev A; Jandoc R; Gula LJ; Oliver MJ; Wald R; Garg AX
PLoS One; 2016; 11(8):e0160768. PubMed ID: 27513855
[TBL] [Abstract][Full Text] [Related]
2. Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
Lin YT; Lu TS; Hansen RA; Wang CC
Clin Ther; 2019 Jun; 41(6):1128-1138.e8. PubMed ID: 31178037
[TBL] [Abstract][Full Text] [Related]
3. Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults.
Aakjaer M; Werther SK; De Bruin ML; Andersen M
Clin Transl Sci; 2022 Sep; 15(9):2105-2115. PubMed ID: 35733364
[TBL] [Abstract][Full Text] [Related]
4. High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.
Ray WA; Chung CP; Murray KT; Hall K; Stein CM
J Clin Psychiatry; 2017 Feb; 78(2):190-195. PubMed ID: 27736049
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.
Assimon MM; Pun PH; Al-Khatib SM; Brookhart MA; Gaynes BN; Winkelmayer WC; Flythe JE
Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):670-679. PubMed ID: 35285107
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults.
Haddad YK; Kakara R; Marcum ZA
J Am Geriatr Soc; 2022 May; 70(5):1450-1460. PubMed ID: 35132611
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
Zivin K; Pfeiffer PN; Bohnert AS; Ganoczy D; Blow FC; Nallamothu BK; Kales HC
Am J Psychiatry; 2013 Jun; 170(6):642-50. PubMed ID: 23640689
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
9. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
[TBL] [Abstract][Full Text] [Related]
10. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
12. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
Kaplan C; Zhang Y
J Ment Health Policy Econ; 2012 Dec; 15(4):171-8. PubMed ID: 23525835
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
Kennedy SH; Andersen HF; Thase ME
Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events.
Czaja AS; Valuck RJ; Anderson HD
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):607-14. PubMed ID: 23456956
[TBL] [Abstract][Full Text] [Related]
16. Differential Associations of Specific Selective Serotonin Reuptake Inhibitors With Resting-State Heart Rate and Heart Rate Variability: Implications for Health and Well-Being.
Kemp AH; Fráguas R; Brunoni AR; Bittencourt MS; Nunes MA; Dantas EM; Andreão RV; Mill JG; Ribeiro AL; Koenig J; Thayer JF; Benseñor IM; Lotufo PA
Psychosom Med; 2016 Sep; 78(7):810-8. PubMed ID: 27219492
[TBL] [Abstract][Full Text] [Related]
17. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
[TBL] [Abstract][Full Text] [Related]
19. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Assimon MM; Brookhart MA; Flythe JE
J Am Soc Nephrol; 2019 Apr; 30(4):611-623. PubMed ID: 30885935
[TBL] [Abstract][Full Text] [Related]
20. Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case-Control Study.
Czaja AS; Anderson HD; Ghosh D; Davidson J; Campbell JD; Valuck RJ
J Pediatr; 2020 Nov; 226():173-178.e8. PubMed ID: 32645405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
